eGFR: Which Tests to Order Alongside for a Complete Kidney Picture

What eGFR Actually Tells You (and What It Misses)

Estimated glomerular filtration rate, or eGFR, is a calculated value derived from serum creatinine, age, and sex using the CKD-EPI 2021 equation. It approximates how many milliliters of blood your kidneys filter per minute, normalized to body surface area. A result of 90 mL/min/1.73 m² or higher, in the absence of proteinuria or structural abnormalities, is considered normal [1].

But creatinine is a flawed surrogate. Muscle mass, diet, hydration, and certain medications (trimethoprim, cimetidine) can shift serum creatinine without any real change in kidney function [2]. A 2021 analysis in the New England Journal of Medicine showed that the race-free CKD-EPI equation reclassified 17.2% of patients compared with the older race-adjusted formula, moving many into higher CKD stages that changed their treatment eligibility [1]. This single number cannot distinguish between stable CKD, acute kidney injury, and normal physiological variation. That is precisely why guidelines from KDIGO insist on paired testing [3].

"No single biomarker should be used in isolation to diagnose or stage CKD," the 2024 KDIGO Clinical Practice Guideline states. "GFR category and albuminuria category together determine risk and guide management" [3].

Urine Albumin-to-Creatinine Ratio: The Most Important Add-On

The uACR is not optional. Pair it with every eGFR order. KDIGO classifies CKD using a heat map that plots eGFR stages (G1 through G5) against albuminuria categories (A1, A2, A3), and neither axis alone captures prognosis [3]. A patient with an eGFR of 55 mL/min/1.73 m² and a uACR of 250 mg/g faces a vastly different trajectory than one with the same eGFR and a uACR under 30 mg/g.

The data behind this pairing is large. A meta-analysis of 45 cohorts including over 1.5 million individuals found that albuminuria and reduced eGFR were independent, additive predictors of kidney failure and cardiovascular death [4]. Patients with eGFR 45 to 59 and uACR 30 to 299 mg/g had a 5-year kidney failure risk roughly 6 times higher than those with the same eGFR but normal albuminuria.

A spot urine sample is sufficient. First-morning void is ideal because it reduces orthostatic proteinuria artifacts, but a random sample is acceptable for screening [5]. The American Diabetes Association (ADA) recommends annual uACR screening for all patients with type 2 diabetes and for anyone with type 1 diabetes lasting five years or more, regardless of eGFR [6].

Cystatin C: Confirming or Correcting the Creatinine-Based Estimate

Cystatin C is a small protein filtered by the glomerulus and not significantly affected by muscle mass or diet. When a creatinine-based eGFR falls between 45 and 59 mL/min/1.73 m² (the diagnostic threshold for stage 3a CKD), the 2024 KDIGO guideline recommends confirming with a cystatin C-based or combined creatinine-cystatin C equation before labeling the patient with CKD [3].

The reclassification rate is significant. A study published in the New England Journal of Medicine (Inker et al., 2021, N=9,366) demonstrated that the combined CKD-EPI creatinine-cystatin C equation reclassified 29.1% of participants compared with the creatinine-only equation [1]. In many cases, patients who appeared to have stage 3a CKD were reclassified upward to stage 2 or normal, sparing them unnecessary referrals and medication restrictions.

Order cystatin C when creatinine-based eGFR is borderline (45 to 69 mL/min/1.73 m²), when the patient has extremes of muscle mass (bodybuilders, amputees, sarcopenic older adults), or when you need precision for drug dosing decisions.

Basic Metabolic Panel: Electrolytes That Shift Early

A basic metabolic panel (BMP) includes sodium, potassium, chloride, bicarbonate, BUN, creatinine, calcium, and glucose. Several of these change predictably as kidney function declines.

Potassium begins to rise when eGFR drops below 30 mL/min/1.73 m², though medications like ACE inhibitors and potassium-sparing diuretics can push hyperkalemia earlier [7]. Bicarbonate falls as the kidneys lose their ability to excrete acid, and metabolic acidosis (serum bicarbonate <22 mEq/L) in CKD is associated with faster disease progression [8]. A 2020 Cochrane review of 15 trials (N=2,445) found that oral bicarbonate supplementation in CKD patients slowed eGFR decline by approximately 3.1 mL/min/1.73 m² over 2 years compared with controls [8].

BUN-to-creatinine ratio helps distinguish prerenal azotemia from intrinsic kidney disease. Glucose on the BMP serves as an immediate check on glycemic control, given that diabetes accounts for approximately 38% of end-stage kidney disease in the United States according to the United States Renal Data System [9].

Complete Blood Count: Catching Anemia Before Symptoms Appear

Erythropoietin production drops as functional kidney mass declines. Anemia of CKD can appear as early as stage 3a (eGFR 45 to 59), though it becomes clinically significant more often in stage 3b and beyond [10]. The KDIGO anemia guideline recommends checking hemoglobin at least annually in CKD stage 3, twice yearly in stages 4 and 5, and every three months in dialysis patients [10].

A CBC also reveals platelet abnormalities (uremic platelet dysfunction) and white cell counts relevant to infection risk. When hemoglobin drops below 10 g/dL in a patient with CKD 3b or worse, clinicians should add iron studies (ferritin and TSAT) to determine whether iron supplementation alone may correct the deficit before considering erythropoiesis-stimulating agents [10].

Lipid Panel: Cardiovascular Risk Dominates CKD Outcomes

Patients with CKD are far more likely to die from cardiovascular disease than to progress to dialysis. This is not a small difference. A landmark cohort study (Go et al., 2004, N=1,120,295) published in the New England Journal of Medicine showed that patients with eGFR 15 to 29 mL/min/1.73 m² had a cardiovascular event rate of 36.6 per 100 person-years, compared with 2.1 per 100 person-years in those with eGFR ≥60 [11].

The 2013 KDIGO lipid guideline recommends a fasting lipid panel at CKD diagnosis and advises statin or statin-ezetimibe therapy for all adults aged 50 and older with eGFR <60 mL/min/1.73 m² not on dialysis, without requiring an LDL target [12]. For patients aged 18 to 49 with CKD, treatment is recommended if they have known coronary disease, diabetes, prior ischemic stroke, or a 10-year coronary event risk exceeding 10%.

"In CKD patients not treated with dialysis, we recommend treatment with a statin or statin/ezetimibe combination," the KDIGO Lipids Work Group wrote [12].

Hemoglobin A1c and Fasting Glucose: The Diabetes-Kidney Axis

Type 2 diabetes is the leading cause of CKD globally. An HbA1c ordered alongside eGFR identifies undiagnosed diabetes, tracks glycemic control in known diabetics, and informs medication selection. This pairing matters for dosing. Metformin requires eGFR ≥30 mL/min/1.73 m² per the FDA-revised label, and the dose should be halved when eGFR falls below 45 [13]. GLP-1 receptor agonists like semaglutide and tirzepatide do not require renal dose adjustment, but their prescribing still depends on knowing the patient's baseline kidney function to monitor for acute changes [14].

SGLT2 inhibitors deserve special mention. The DAPA-CKD trial (N=4,304) showed that dapagliflozin reduced the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal death by 44% (HR 0.56 to 95% CI 0.45 to 0.68) compared with placebo in patients with CKD, regardless of diabetes status [15]. HbA1c helps clinicians determine whether the SGLT2 inhibitor is being added for glycemic control, kidney protection, or both.

Intact PTH and Vitamin D: Bone-Mineral Metabolism in CKD

CKD-mineral bone disorder (CKD-MBD) begins long before patients reach dialysis. The kidneys convert 25-hydroxyvitamin D to its active form (1,25-dihydroxyvitamin D), so active vitamin D levels drop as nephron mass declines. Parathyroid hormone rises in compensation, accelerating bone turnover and vascular calcification [16].

KDIGO recommends measuring intact PTH and 25-hydroxyvitamin D starting at CKD stage 3 (eGFR <60), with monitoring intervals tightening as disease progresses: annually in stage 3, every 6 to 12 months in stage 4, and every 3 to 6 months in stage 5 [16]. Serum phosphorus and calcium should be checked concurrently. A phosphorus level above 4.5 mg/dL in CKD stages 3 to 5 (not on dialysis) triggers dietary counseling and possible phosphate binder therapy [16].

Patients on testosterone replacement therapy (TRT) or hormone replacement therapy (HRT) should have these markers tracked with extra attention. Both testosterone and estrogen influence bone density, and their interaction with CKD-MBD can complicate fracture risk assessment [17].

Serum Uric Acid: An Emerging Add-On

Uric acid's role in CKD progression is debated, but the data is growing. A 2020 meta-analysis of 13 cohort studies (N=190,718) found that each 1 mg/dL increase in serum uric acid was associated with an 11% higher risk of incident CKD (pooled RR 1.11 to 95% CI 1.08 to 1.14) [18]. Whether treating hyperuricemia slows CKD is less clear. The CKD-FIX trial (N=369) found no benefit of allopurinol on eGFR decline over 2 years [19].

Still, ordering uric acid alongside eGFR is useful for patients on thiazide diuretics (which raise uric acid), patients with gout, and patients starting SGLT2 inhibitors (which lower uric acid by 10 to 15% through increased uricosuria) [20]. The test is inexpensive and can inform the full metabolic picture without adding clinical complexity.

Urinalysis with Microscopy: The Low-Cost High-Yield Pairing

A standard urinalysis with microscopy adds context that no blood test can provide. Hematuria with dysmorphic red blood cells suggests glomerulonephritis. White cell casts point to interstitial nephritis. Waxy or broad casts indicate chronic damage. These findings change the diagnostic workup entirely and can trigger a nephrology referral even when eGFR appears only mildly reduced [21].

The ADA Standards of Care 2024 recommend urinalysis at diabetes diagnosis and then as clinically indicated [6]. For patients without diabetes, the USPSTF does not recommend universal CKD screening, but targeted urinalysis in high-risk populations (hypertension, family history, obesity) is considered good practice [22].

Putting the Panel Together: A Practical Ordering Framework

The minimum paired order for any eGFR is a uACR. Everything else scales with the clinical scenario.

For a screening visit in a patient with hypertension or diabetes: order eGFR, uACR, BMP, HbA1c, fasting lipid panel, and CBC. This six-test bundle covers CKD staging, electrolyte shifts, glycemic status, cardiovascular risk, and early anemia detection.

For a patient with confirmed CKD stage 3 or worse: add cystatin C (if not yet done), intact PTH, 25-OH vitamin D, serum phosphorus, and uric acid. Repeat eGFR and uACR every 3 to 6 months depending on trajectory, and track PTH and vitamin D every 6 to 12 months [3].

For medication-specific scenarios: if starting metformin, confirm eGFR ≥30 with cystatin C if borderline. If starting an SGLT2 inhibitor, obtain baseline uACR (the benefit signal is strongest in patients with albuminuria ≥200 mg/g) [15]. If starting or adjusting GLP-1 agonist therapy, monitor eGFR at baseline and at 3 months to detect rare acute kidney injury.